Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × niraparib × Clear all

Phase

Status

Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 8 Prostatic Neoplasms 5 Breast Neoplasms 4 Neoplasms 3 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2 Prostatic Neoplasms, Castration-Resistant 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Glioma 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Uterine Cervical Neoplasms 1 Solid Tumor 1 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Neoplasm, Residual 1 Metastatic Castration-sensitive Prostate Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Disease Progression 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Neuroendocrine 1

Interventions

Cyclophosphamide 18 Dexamethasone 15 fludarabine 11 Rituximab 7 pomalidomide 6 pembrolizumab 6 fludarabine phosphate 6 daratumumab 6 carfilzomib 6 venetoclax 5 Lenalidomide 5 Gemcitabine 5 Cisplatin 5 Calcium Dobesilate 5 Nivolumab 4 Etoposide 4 Bortezomib 4 isatuximab 3 elotuzumab 3 Vincristine 3 Prednisone 3 Ipilimumab 3 Injections 3 Doxorubicin 3 Carboplatin 3 tisagenlecleucel 2 ruxolitinib 2 obinutuzumab 2 dexamethasone 21-phosphate 2 cabazitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡